![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
ABT530+ABT493 Pangenotypic in Phase 2B
|
|
|
"Preliminary results from a Phase 2b study (n=79) of ABT-493 and ABT-530 in non-cirrhotic GT1 patients receiving the RBV-free recommended regimen for 12 weeks demonstrated a sustained virologic response rate at four weeks post treatment (SVR4) of 99 percent (n=78/79)."
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection n=175
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection
EASL: Potent Antiviral Activity of ABT-493 and ABT-530 With 3-Day Monotherapy in Patients With and Without Compensated Cirrhosis With Hepatitis C Virus (HCV) Genotype 1 Infection - (05/04/15)
EASL: Steady-State Pharmacokinetics and Safety of Co-administration of Pan-Genotypic Direct Acting Protease Inhibitor ABT-493 with Pan-Genotypic NS5A Inhibitor ABT-530 in Healthy Adult Subjects - (05/04/15)
EASL: Pharmacokinetics of ABT-493 and ABT-530 is Similar in Healthy Caucasian, Han Chinese, and Japanese Adult Subjects - (05/04/15)
ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage......
http://www.natap.org/2014/CROI/croi_14.htm
A Next Generation HCV DAA Combination: Potent, Pangenotypic Inhibitors ABT-493 and ABT-530 With High Barriers to Resistance......
http://www.natap.org/2014/AASLD/AASLD_51.htm
ABT-530, an HCV NS5A Inhibitor With Potent Pangenotypic Activity and High Genetic Barrier to Resistance.....
http://www.natap.org/2014/CROI/croi_11.htm
EASL - The International Liver Congress 2015 50th Annual Meeting of the European
Association for the Study of the Liver Vienna, Austria April 22-26
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|